Novartis backs brolucizumab with new head-to-head Eylea trial

pharmaphorum | September 09, 2019

Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial in the wet form of AMD will compare brolucizumab against Eylea (aflibercept) on a range of measures, including visual acuity and treatment interval duration, to see if it can outperform Bayer and Regeneron’s drug. An FDA verdict on brolucizumab is due shortly based on two earlier trials – HAWK and HARRIER – and the company is hoping to launch its new therapy before the end of the year in the US. Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported sales of $2 billion for Lucentis last year, with its marketing partner Roche adding another $1.7 billion in US sales. In comparison, Regeneron posted $4 billion revenues from the US while Bayer made $2.1 billion in ex-US Eylea sales. Brolucizumab is seen as Novartis’ big chance to claim back dominance of the wet AMD market, which has seen first-to-market Lucentis progressively caught up and overtaken by Eylea over the last few years, and the company spent a priority review voucher in order to get the FDA review done as quickly as possible.

Spotlight

Sen. Bernie Sanders (I-VT) indicates that his single payer proposal eliminates drug companies during an interview with CBS News’ Ed O'Keefe. Be sure to like, subscribe, and comment below to share your thoughts on the video.

Related News

Zeblok Computational Announces Partnership with Laufer Center and CEWIT - COVID-19 Drug Discovery

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein targets: The RNA-dependent RNA polymerase (which copies the virus inside the cell, thought to be the target of Gilead’s Remdesivir, now in clinical trials) The Protease (which chops up the virus proteins into the right pieces) The spike protein (which is how the virus unlocks the door to enter the cell).

Read More

RESEARCH

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. Algernon recently established a clinical research program for the treatment of stroke zeroed in on DMT, a known psychedelic compound that is part of the tryptamine family. The Company plans to be the principal company globally to seek after DMT for stroke in humans and is planning to begin a clinical trial as soon as conceivable in 2021. The Company's decision to investigate DMT, called "The Spirit Molecule," and move it into human trials for stroke, is based on various independent, positive preclinical studies demonstrating that DMT advances neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration. By pursuing a continuous active microdose, the goal will be to provide patients with the therapeutic benefits of DMT, without having a psychedelic experience. This is an important element when considering treating a patient who has quite recently endured a stroke, wherein medications that cause a hallucinogenic response would cause unwanted confusion and stress. DMT Background N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing impacts similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT happens naturally in many plant species and animals and has been utilized in strict ceremonies as a traditional spiritual medicine by indigenous individuals in the Amazonian basin. DMT can also be synthesized in a laboratory. At higher portions, DMT has a rapid onset, intense psychedelic impacts, and a relatively short duration of action with an estimated half-existence of under fifteen minutes. Like other hallucinogens in the tryptamine family, DMT binds to serotonin receptors to deliver euphoria and psychedelic impacts. Because the impacts of DMT don't last long, it has been alluded to in certain circles as the "businessman's outing". Named the "Spirit Molecule" by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, and Algernon consultant, DMT has been shown to induce neuroplasticity in a number of key preclinical studies DMT is believed to activate pathways involved with forming neuron connections and has been shown in studies to increase the number of dendritic spines on cortical neurons. Dendritic spines form synapses (connections) with other neurons and are a major site of molecular activity in the brain. While Dr. Strassman's Phase 1 bolus intravenous human study identified the sub-hallucinogenic portion of DMT in humans, another preclinical animal study demonstrated this same portion level actually retains the neuroplastic impact seen in higher hallucinogenic dosages. Algernon will be investigating an intravenous sub-hallucinogenic portion of DMT in its research and clinical studies. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Read More

Nelson pharmacy fined $344,000 and director $50,000 for price-fixing

Miragenews | June 07, 2020

The Wellington High Court has ordered Prices Pharmacy 2011 Limited and a director of the company, Stuart Hebberd, to pay fines of $344,000 and $50,000 respectively, after they admitted engaging in price-fixing in breach of the Commerce Act. The Commission filed proceedings in April 2018 alleging that Prices Pharmacy 2011 Limited and its directors facilitated a price-fixing arrangement with competing Nelson pharmacies in May 2016, in breach of Part 2 of the Commerce Act. In most cases, the arrangement resulted in consumers paying $6, instead of $5, for their prescription items.

Read More

Spotlight

Sen. Bernie Sanders (I-VT) indicates that his single payer proposal eliminates drug companies during an interview with CBS News’ Ed O'Keefe. Be sure to like, subscribe, and comment below to share your thoughts on the video.